Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online December 4, 2007
Diabetes Care 31:562-568, 2008
DOI: 10.2337/dc07-1526
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-1526v1
31/3/562    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Musso, G.
Right arrow Articles by Cassader, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Musso, G.
Right arrow Articles by Cassader, M.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cardiovascular and Metabolic Risk
Original Research

Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome?

A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects

Giovanni Musso, MD1, Roberto Gambino, MD2, Simona Bo, MD2, Barbara Uberti, MD2, Giampaolo Biroli, MD2, Gianfranco Pagano, MD2 and Maurizio Cassader, MD2

1 Gradenigo Hospital, Turin, Italy
2 Department of Internal Medicine, University of Turin, Turin, Italy

Address correspondence and reprint requests to Giovanni Musso, Gradenigo Hospital, Corso R. Margherita 8, 10132 Turin, Italy. E-mail: giovanni_musso{at}yahoo.it

OBJECTIVE—The ability of the Adult Treatment Panel III (ATP III) criteria of metabolic syndrome to identify insulin-resistant subjects at increased cardiovascular risk is suboptimal, especially in the absence of obesity and diabetes. Nonalcoholic fatty liver disease (NAFLD) is associated with insulin resistance and is emerging as an independent cardiovascular risk factor. We compared the strength of the associations of ATP III criteria and of NAFLD to insulin resistance, oxidative stress, and endothelial dysfunction in nonobese nondiabetic subjects.

RESEARCH DESIGN AND METHODS—Homeostasis model assessment of insulin resistance (HOMA-IR) >2, oxidative stress (nitrotyrosine), soluble adhesion molecules (intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin), and circulating adipokines (tumor necrosis factor-{alpha}, leptin, adiponectin, and resistin) were cross-sectionally correlated to ATP III criteria and to NAFLD in 197 unselected nonobese nondiabetic subjects.

RESULTS—NAFLD more accurately predicted insulin resistance than ATP III criteria: sensitivity 73 vs. 38% (P = 0.0001); positive predictive value: 81 vs. 62% (P = 0.035); negative predictive value 87 vs. 74% (P = 0.012); positive likelihood ratio 4.39 vs. 1.64 (P = 0.0001); and negative likelihood ratio 0.14 vs. 0.35 (P = 0.0001). Adding NAFLD to ATP III criteria significantly improved their diagnostic accuracy for insulin resistance. Furthermore, NAFLD independently predicted HOMA-IR, nitrotyrosine, and soluble adhesion molecules on logistic regression analysis; the presence of NAFLD entailed more severe oxidative stress and endothelial dysfunction, independent of adiposity or any feature of the metabolic syndrome in insulin-resistant subjects.

CONCLUSIONS—NAFLD is more tightly associated with insulin resistance and with markers of oxidative stress and endothelial dysfunction than with ATP III criteria in nonobese nondiabetic subjects and may help identify individuals with increased cardiometabolic risk in this population.

Abbreviations: ALT, alanine aminotransferase • ATP III, Adult Treatment Panel III • HOMA-IR, homeostasis model assessment of insulin resistance • ICAM-1, intercellular adhesion molecule-1 • NAFLD, nonalcoholic fatty liver disease • OGTT, oral glucose tolerance test • TNF-{alpha}, tumor necrosis factor-{alpha} • VCAM-1, vascular cell adhesion molecule-1


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
G. Musso, R. Gambino, S. Bo, and M. Cassader
Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? A Cross-Sectional Comparison With Adult Treatment Panel III Criteria in Nonobese Nondiabetic Subjects: Response to Sookoian et al.
Diabetes Care, May 1, 2008; 31(5): e43 - e43.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.